Opus Point Partners Management as of June 30, 2017
Portfolio Holdings for Opus Point Partners Management
Opus Point Partners Management holds 60 positions in its portfolio as reported in the June 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| SPDR S&P Biotech (XBI) | 9.2 | $10M | 130k | 77.18 | |
| Proshares Tr pshs ult nasb (BIB) | 8.5 | $9.2M | 173k | 53.40 | |
| iShares NASDAQ Biotechnology Index (IBB) | 7.1 | $7.8M | 25k | 310.08 | |
| Bristol Myers Squibb (BMY) | 6.9 | $7.5M | 135k | 55.72 | |
| Alexion Pharmaceuticals | 5.0 | $5.4M | 45k | 121.67 | |
| Merck & Co (MRK) | 4.9 | $5.4M | 84k | 64.09 | |
| AstraZeneca (AZN) | 3.8 | $4.1M | 120k | 34.09 | |
| Alnylam Pharmaceuticals (ALNY) | 3.6 | $3.9M | 49k | 79.76 | |
| Pfizer (PFE) | 3.5 | $3.8M | 112k | 33.59 | |
| GlaxoSmithKline | 2.4 | $2.6M | 60k | 43.12 | |
| Alkermes (ALKS) | 2.3 | $2.5M | 43k | 57.97 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.2 | $2.4M | 19k | 128.88 | |
| Incyte Corporation (INCY) | 2.1 | $2.2M | 18k | 125.90 | |
| Regeneron Pharmaceuticals (REGN) | 2.0 | $2.2M | 4.5k | 491.17 | |
| Ionis Pharmaceuticals (IONS) | 2.0 | $2.2M | 44k | 50.88 | |
| Mettler-Toledo International (MTD) | 1.9 | $2.1M | 3.6k | 588.48 | |
| Nektar Therapeutics (NKTR) | 1.8 | $1.9M | 97k | 19.55 | |
| Qiagen Nv | 1.8 | $1.9M | 57k | 33.52 | |
| Celgene Corporation | 1.7 | $1.9M | 14k | 129.88 | |
| Seattle Genetics | 1.7 | $1.8M | 35k | 51.75 | |
| Ignyta | 1.6 | $1.8M | 171k | 10.35 | |
| Illumina (ILMN) | 1.6 | $1.7M | 9.9k | 173.47 | |
| Amgen (AMGN) | 1.6 | $1.7M | 9.8k | 172.18 | |
| Biogen Idec (BIIB) | 1.4 | $1.6M | 5.8k | 271.42 | |
| BioMarin Pharmaceutical (BMRN) | 1.4 | $1.5M | 17k | 90.80 | |
| Agios Pharmaceuticals (AGIO) | 1.4 | $1.5M | 30k | 51.46 | |
| Clovis Oncology | 1.3 | $1.4M | 15k | 93.60 | |
| Eli Lilly & Co. (LLY) | 1.1 | $1.2M | 15k | 82.33 | |
| Pacira Pharmaceuticals (PCRX) | 1.1 | $1.2M | 25k | 47.72 | |
| Loxo Oncology | 1.0 | $1.1M | 14k | 80.22 | |
| Direxion Shs Etf Tr sp biotch bl | 0.9 | $1.0M | 16k | 63.05 | |
| Paratek Pharmaceuticals | 0.9 | $964k | 40k | 24.10 | |
| Gilead Sciences (GILD) | 0.9 | $936k | 13k | 70.64 | |
| Karyopharm Therapeutics (KPTI) | 0.8 | $905k | 100k | 9.05 | |
| Axsome Therapeutics (AXSM) | 0.7 | $734k | 134k | 5.50 | |
| Tesaro | 0.6 | $699k | 5.0k | 139.80 | |
| Kite Pharma | 0.6 | $613k | 5.9k | 103.63 | |
| Medicines Company | 0.5 | $532k | 14k | 38.00 | |
| Myriad Genetics (MYGN) | 0.5 | $527k | 20k | 25.82 | |
| Juno Therapeutics | 0.5 | $537k | 18k | 29.88 | |
| Adamas Pharmaceuticals | 0.5 | $525k | 30k | 17.50 | |
| Intrexon | 0.4 | $442k | 18k | 24.09 | |
| New Senior Inv Grp | 0.4 | $421k | 42k | 10.06 | |
| Axovant Sciences | 0.4 | $404k | 17k | 23.19 | |
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $382k | 6.2k | 62.04 | |
| Akebia Therapeutics (AKBA) | 0.3 | $302k | 21k | 14.37 | |
| Grifols S A Sponsored Adr R (GRFS) | 0.2 | $272k | 13k | 21.11 | |
| Charles River Laboratories (CRL) | 0.2 | $259k | 2.6k | 101.09 | |
| Ligand Pharmaceuticals In (LGND) | 0.2 | $257k | 2.1k | 121.63 | |
| Quintiles Transnatio Hldgs I | 0.2 | $261k | 2.9k | 89.35 | |
| Bio-techne Corporation (TECH) | 0.2 | $248k | 2.1k | 117.42 | |
| Neurocrine Biosciences (NBIX) | 0.2 | $238k | 5.2k | 45.99 | |
| Intercept Pharmaceuticals In | 0.2 | $220k | 1.8k | 120.88 | |
| Heron Therapeutics (HRTX) | 0.2 | $220k | 16k | 13.86 | |
| Contrafect | 0.2 | $218k | 150k | 1.45 | |
| Iovance Biotherapeutics (IOVA) | 0.2 | $220k | 30k | 7.35 | |
| Avexis | 0.2 | $205k | 2.5k | 82.00 | |
| Recro Pharma | 0.2 | $177k | 25k | 7.02 | |
| Progenics Pharmaceuticals | 0.1 | $148k | 22k | 6.79 | |
| Scynexis | 0.1 | $119k | 67k | 1.79 |
